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The two fixed-dose combinations of dihydroartemisinin and piperaquine (Artekin and Arterakine) were
found to be bioinequivalent in healthy Vietnamese subjects. However, because the peak plasma concen-
trations and areas under the concentration-time curves of dihydroartemisinin and piperaquine were only
marginally different between the two formulations, similar therapeutic efficacies are expected in the
treatment of malaria infections.
Artemisinin-based combination treatments (ACTs) are now
considered the best therapy for the treatment of Plasmodium
falciparum malaria (13, 19). One of the most promising ACTs
is the fixed-dosed dihydroartemisinin-piperaquine combina-
tion marketed as Artekin (Holleykin Pharmaceuticals Co. Ltd.,
China), which is well tolerated and highly effective in the treat-
ment of P. falciparum malaria (2, 3, 8, 14). The cure rate for
Artekin is typically greater than 95% following a 3-day course,
with a 42-day follow-up period. Despite the availability of clin-
ical data on the efficacy of Artekin, no pharmacokinetic data
are available on dihydroartemisinin given as an oral coformu-
lation with piperaquine and few data are available on the
disposition of piperaquine following Artekin administration.
Recently, the Vietnamese Ministry of Health licensed Cen-
tral Pharmaceutical Company No. 1 to produce a fixed-dose
combination of dihydroartemisinin-piperaquine, marketed as
Arterakine, for use in Vietnam. In the present study, we com-
pared the pharmacokinetics of the components of Artekin and
Arterakine and assessed the bioequivalence of Arterakine to
the reference formulation, Artekin.
A randomized, open-label, single-dose, two-period crossover
study was carried out with 24 healthy male Vietnamese sub-
jects with a mean ( standard deviation) age of 21.0 (2.7) years
and a mean weight of 59.7 (3.3) kg. Each subject received three
tablets of the reference drug, Artekin (batch no. 20040201;
each tablet contains 40 mg dihydroartemisinin and 320 mg
piperaquine phosphate; Holleykin Pharmaceutical Co. Ltd.,
Guangdong, China), and three tablets of the test drug, Arter-
akine (batch no. 010606; each tablet contains 40 mg dihydro-
artemisinin and 320 mg piperaquine phosphate; Central Phar-
maceutical Factory No. 1, Hanoi, Vietnam). The study was
carried out within the 3-year expiration period of the medica-
tion, and the washout period between the two treatment
phases was 10 weeks. The study was approved by the Review
and Scientific Board of Central Military Hospital 108 and
the Australian Defense Human Research Ethics Committee
(ADHREC 437/06).
Each subject received the medication after an overnight fast
(no food for 8 h), and the tablets were taken with 200 ml of
water. Food was withheld for 4 h after drug administration.
Beverages containing caffeine, alcohol, or grapefruit juice and
smoking were not allowed 2 days before and after drug admin-
istration. Venous blood samples (7 ml) were collected with an
indwelling cannula within 0.5 h (baseline) prior to dosing and
at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 h after drug
administration. Subsequent blood samples were collected by
venipuncture at days 1, 3, 7, 14, 21, and 28 after dosing. Blood
samples were centrifuged, and the separated plasma samples
(3 ml) were stored at 80°C until analyzed, which was within
12 months of collection.
Plasma concentrations of dihydroartemisinin were measured
by liquid chromatography-tandem mass spectrometry. Briefly,
to a glass tube fitted with a Teflon-lined cap were added
plasma (200 l) and alprazolam (internal standard, 50 l of a
150-ng/ml concentration) and the contents were mixed prior to
the addition of butyl chloride-ethyl acetate (9:1, vol/vol; 3 ml).
The tubes were rotated for 5 min and then centrifuged (3,000 
g for 5 min). The organic layer was transferred to a clean glass
tube and evaporated to dryness under a stream of air at 37°C.
Chromatographic analysis was conducted with a Prominence
liquid chromatography system (Shimadzu, Japan) and an HTC
PAL autosampler (CTC Analytics, Switzerland) linked to an
API3200 mass spectrometer (Applied Biosystems) fitted with
an electrospray interface operated in the positive-ion mode.
The reconstituted sample was separated on a Luna C18 high-
performance liquid chromatography column (50 by 2.0 mm
[inside diameter], 3-m particle size; Phenomenex) preceded
by a Luna C18 guard cartridge with an acetonitrile-ammonium
acetate gradient at a flow rate of 0.4 ml/min. The peak area
ratios of the NH adduct of dihydroartemisinin (product at
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m/z 267.2 from the parent ion at m/z 302.2) to the internal
standard (product at m/z 281.2 from the parent ion at m/z
309.2) were calculated for each sample from the measured
peak areas obtained by selected reaction monitoring. The re-
tention times of the internal standard and dihydroartemisinin
were 2.0 and 2.2 min, respectively. Quadratic regression of the
concentration data (range, 1 to 1,000 ng/ml) with 1/concentra-
tion2 (2) weighting yielded a correlation coefficient of 0.994
for dihydroartemisinin. The lower limit of quantification was 1
ng/ml with 0.2 ml of plasma. The overall precision of analysis
for dihydroartemisinin, as defined by the percent coefficient of
variation of spiked samples was 6.3% at 1 ng/ml, 5.7% at 20
ng/ml, 4.6% at 200 ng/ml, and 6.6% at 750 ng/ml. The corre-
sponding inaccuracy values were 1.3%, 1.5%, 0.7%, and
3.2%. Plasma concentrations of piperaquine were measured by
a validated high-performance liquid chromatography method
(10). The precision of the assay was 10.3% at 10 ng/ml, 6.8% at
100 ng/ml, and 6.7% at 500 ng/ml. The corresponding inaccu-
racy values were 11%, 3%, and 1%. The lower limit of quan-
tification of piperaquine was 5 ng/ml with 0.5 ml of plasma.
Pharmacokinetic parameters (peak concentration [Cmax], time
to reach maximum concentration [Tmax], area under the concen-
tration-time curve from 0 h to the last data point [AUC03last] and
from the last data point to infinity [AUClast3], terminal half-life
[t1/2], apparent oral clearance [CL/F], and apparent volume of
distribution [V/F]) were determined from the plasma concentra-
tion-time data by noncompartmental methods (5). The pharma-
cokinetic parameters of dihydroartemisinin and piperaquine were
calculated from the nominal potency of the tablets and tested
parametrically with the paired t test for statistically significant
differences between the two formulations. Schuirmann’s two one-
sided t test procedure was used to calculate the 90% confidence
interval (CI) from the log-transformed pharmacokinetic data
(15). Treatments were considered bioequivalent if the 90% CI for
mean point estimators (ratio of test/reference) for the Cmax and
AUC of dihydroartemisinin and piperaquine fell within the ac-
ceptance range of 80 to 125% for log-transformed values (4). The
effects of formulation, period, and sequence effects were studied
by analyses of variance (ANOVA) of the log-transformed data.
The mean plasma concentration-time profiles of dihydroarte-
misinin after a single oral dose of Arterakine and Artekin are
shown in Fig. 1, and the pharmacokinetics of dihydroartemisinin
are summarized in Table 1.The geometric mean Cmax of dihydro-
artemisinin was higher and was achieved marginally faster after
Arterakine (Cmax, 198 ng/ml; mean Tmax, 1.0 h) than after Artekin
(Cmax, 159 ng/ml; Tmax, 1.5 h) administration. The AUC03last of
dihydroartemisinin was higher after Arterakine than after Ar-
tekin administration, with geometric mean values of 442 and 366
ng  h/ml, respectively, but the difference was not significant (P
0.05). Dihydroartemisinin was rapidly eliminated, with a t1/2 of
about 1 h for the two formulations. There was a significant dif-
ference in the CL/F (4.95 versus 5.87 liters/h/kg; 95% CI, 1.72,
0.12; P	 0.03) and V/F of dihydroartemisinin (7.00 versus 8.02
liters/kg; 95% CI, 3.10, 0.13; P 	 0.03) following the admin-
istration of the two formulations. Overall, the pharmacokinetics
of dihydroartemisinin after Arterakine or Artekin administration
were comparable to values obtained in healthy Vietnamese and
Thai subjects given dihydroartemisinin alone (9, 11). Thus, pip-
eraquine does not appear to alter the pharmacokinetics of dihy-
droartemisinin when given as a coformulation.
The mean plasma concentration-time profiles and pharma-
cokinetics of piperaquine are presented in Fig. 2 and Table 1,
respectively. The geometric mean Cmax (232 versus 204 ng/ml)
and AUC03last (13,431 versus 11,988 ng  h/ml) of pipera-
quine were higher after Arterakine than after Artekin admin-
istration, but the difference was not significant. After adjusting
for dose and weight differences, the Cmax of piperaquine was
markedly higher in the healthy Vietnamese subjects after the
administration of both ACTs than in healthy Caucasians ad-
ministered piperaquine alone (1, 16). Ethnic differences and
differences in tablet excipients and dissolution behavior may
account for the variations in piperaquine concentrations
achieved after the administration of piperaquine alone and
the two coformulations used in the present study. The elim-
ination of piperaquine (based on measurements from day 7
forward) was lengthy, with an estimated mean t1/2 of about
645 h (26.8 days) in the healthy subjects, which is in good
agreement with values obtained in healthy Vietnamese (6,
12) and Caucasian subjects (16, 18) and in malaria patients
(7, 17). The mean CL/Fs of piperaquine after Arterakine
and Artekin administration of 0.42 and 0.50 liter/h/kg, re-
spectively, were lower than previously reported in healthy
Vietnamese (0.74 liter/h/kg [12]) and Caucasian subjects
(1.14 liters/h/kg [16]) given piperaquine alone. A large V/F
of piperaquine was estimated after Arterakine (377  125
liter/kg) and Artekin (428  170 liter/kg) administration,
which is consistent with the high values reported in healthy
subjects (6, 12, 16) and malaria patients (7, 17).
Statistical evaluation of the pharmacokinetic data for dihydro-
artemisinin and piperaquine showed bioinequivalence of Arter-
akine and Artekin for the Cmax, AUC03last, and AUC03 of
dihydroartemisinin and the Cmax and AUC03 of piperaquine
FIG. 1. Mean (standard error of the mean) plasma dihydroarte-
misinin concentration-time profiles following the administration of a
single oral dose of three Arterakine (F) or Artekin (E) tablets to 24
healthy Vietnamese subjects.
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within the predetermined acceptance range of 80 to 125% at the
90% CI (Table 2). The results of the ANOVA found that formu-
lation, period, and sequence had no statistically significant effects
on the Cmax of dihydroartemisinin and piperaquine. However,
there was a significant effect of formulation on the AUC03last of
dihydroartemisinin (P 	 0.01) and piperaquine (P 	 0.04). Sim-
ilarly, there was a significant effect of period on the AUC03last of
dihydroartemisinin (P	 0.02) and piperaquine (P	 0.03), which
may be a random occurrence but is unlikely to be of importance
given the balanced study design. The sequence had no significant
effect on the AUC03last of either drug.
The mean drug contents based on five tablets of Arterakine
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FIG. 2. Mean (standard error of the mean) plasma piperaquine
concentration-time profiles following the administration of a single
oral dose of three Arterakine (F) or Artekin (E) tablets to 24 healthy
Vietnamese subjects.
TABLE 2. Parametric 90% CIs for the mean pharmacokinetic
properties of dihydroartemisinin and piperaquine after the
administration of a single oral dose of Arterakine and
Artekin (reference formulation)
Drug and parameter Arterakine/Artekinpoint estimator (%) 90% CI
a
Dihydroartemisinin
Cmax 136.4 100.6–152.8
b
AUC0-last 122.0 105.4–137.3
b
AUC0- 121.6 105.0–137.3
b
Cmax/AUC0- 105.9 92.9–114.8
t1/2 95.2 88.7–105.3
Piperaquine
Cmax 116.5 91.3–142.0
b
AUC0-last 111.7 101.6–123.6
AUC0- 115.4 106.5–128.5
b
Cmax/AUC0- 97.7 78.3–121.3
t1/2 100.6 86.4–125.2
b
a Determined by using log-transformed data.
b Value falls outside the range of 80 to 125%.
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were 103.3%  4.4% for dihydroartemisinin and 100.6% 
1.2% for piperaquine. The corresponding contents in the Ar-
tekin tablets were 95.3% 8.3% and 98.8% 2.9%. Although
the lower contents of dihydroartemisinin (8%) and pipera-
quine (1.8%) in the Artekin than in the Arterakine tablets
would have contributed to the bioinequivalence of the two
formulations, after adjustment for drug content, the Cmax and
AUC03 of both drugs were still outside the acceptance range
of 80 to 125% (data not shown).
In conclusion, the pharmacokinetic parameters of dihydro-
artemisinin and piperaquine and the values obtained were
consistent with previous studies in which the drugs were given
alone. Because the bioavailability of dihydroartemisinin and
piperaquine was only marginally higher after Arterakine than
after Artekin administration, the two formulations are ex-
pected to result in similar therapeutic efficacies in the treat-
ment of malaria infections.
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